Wilson Sonsini Goodrich & Rosati advised Absci on the transaction. Absci Corporation (Nasdaq: ABSI) announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Switch Therapeutics on the transaction and launch. Switch Therapeutics, a preclinical stage biotechnology company pioneering a new way to use...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Insilico Medicine, a clinical-stage artificial intelligence-driven drug discovery company, announced a multi-year, multi-target strategic research...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Synthekine on the deal. Synthekine Inc., an engineered cytokine therapeutics company, announced that it has entered into a worldwide research...
You must be a Standard 1 Year member to access this content.
